-
Reduced appetite – Patients often report feeling satisfied sooner and eating less.
Weight loss – Both support steady, clinically meaningful weight loss when combined with lifestyle changes.
-
Redness, swelling, or mild irritation at the injection site (abdomen, thigh, or arm).
Usually mild and temporary. Rotating injection sites helps prevent this.
-
The U.S. Food and Drug Administration (FDA) only approves medications after extensive clinical trials proving safety and effectiveness.
Both Wegovy (semaglutide) and Saxenda (liraglutide) are officially approved by the FDA for chronic weight management, not just for diabetes (though they have roles there too).
FDA approval ensures that these treatments are not experimental — they’ve passed rigorous testing.
-
Lower blood sugar – Both improve insulin sensitivity and reduce glucose spikes, which is particularly beneficial for people with prediabetes or type 2 diabetes.
Improved cholesterol and blood pressure – Weight loss and metabolic effects can lower cardiovascular risk factors over time.
-
Nausea – Very common at the start, especially during dose increases. Often improves after a few weeks.
Vomiting – Can occur if the stomach feels overly full.
Diarrhea – Loose stools are possible but usually settle.
Constipation – In some patients, the slowing of digestion leads to constipation instead of diarrhea.
Bloating, indigestion, or abdominal discomfort – The sensation of “feeling full too quickly” is expected.
💡 Tip for patients: Smaller, more frequent meals and avoiding greasy/spicy foods can reduce these effects.
-
Fatigue or mild weakness (often linked to reduced calorie intake).
Headaches (sometimes from dehydration or appetite suppression).
Dizziness (especially if meals are skipped).
-
Most side effects are mild, but some symptoms need medical attention:
Persistent nausea, vomiting, or diarrhea (risk of dehydration).
Severe stomach pain, especially if it spreads to your back (possible pancreatitis).
Right-sided abdominal pain, fever, or yellowing of the skin/eyes (possible gallbladder issue).
Difficulty breathing, swelling of lips/face, or rash (possible allergic reaction).
Severe constipation lasting several days.
New or worsening mood changes or thoughts of self-harm (rare but important).
Unexplained lumps or swelling in the neck (thyroid-related concerns).
📞 Contact: 0221364380
📍 Address: 1280 Dominion Road
| Feature | Wegovy® | Saxenda®,/a> |
|---|---|---|
| Feature | Wegovy (Semaglutide 2.4 mg) | Saxenda (Liraglutide 3 mg) |
| Dosing Frequency | Once weekly (subcutaneous injection) | Once daily (subcutaneous injection) |
| Average Weight Loss | ~14.9% over 68 weeks | ~5–8% over 56 weeks |
| Appetite Suppression | Strong appetite control due to longer half-life | Milder appetite control |
| Convenience | Fewer injections → easier adherence | Daily injections → requires routine |
| Approval Timeline | FDA approved 2021 – newer, obesity-specific | FDA approved 2014 – first GLP-1 for weight management |
| Metabolic Benefits | Greater improvements in blood sugar & cardiometabolic health | Moderate improvements in blood sugar and metabolic profile |
| Cost & Availability | Often more expensive; may be limited availability | Generally more accessible and widely available |
Just once a week
More patients lose 15% or more of their body weight
Less hassle means better long-term success